NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.

摘要

On Feb 26,2014, the National institute for Health and Care Excellence (NICE) published guidance recommending pixantrone monotherapy as an option for treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in adults who have previously been treated with rituximab and who are receiving third-line or fourth-line treatment, as long as the manufacturer provides pixantrone with the discount agreed in a patient access scheme. Although the evidence base for pixantrone was small-particularly for patients previously treated with rituximab-NICE'S independent appraisal committee concluded that the evidence as a whole was in favour of pixantrone and that the price agreed in the patient access scheme meant that the drug was an acceptable use of National Health Service (NHS) resources.